Hantavirus Registry - HantaReg

Launched by UNIVERSITY OF COLOGNE · Mar 24, 2020

Keywords

ClinConnect Summary

The HantaReg clinical trial is studying hantavirus infections, which can cause serious illnesses like hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS). These infections are becoming more common and can vary in severity. Currently, there is no specific treatment for these diseases, so this study aims to better understand how they progress and the impact they have on health and costs. The trial will involve participants from different countries to gather comprehensive data.

To be eligible for this trial, individuals must have evidence of a hantavirus infection and show clinical signs of either nephropathia epidemica, HFRS, or HCPS. This means that if someone has tested positive for hantavirus and is experiencing symptoms related to these conditions, they may be able to participate. Participants can expect to contribute to important research that could help improve the understanding and management of hantavirus diseases. It’s an opportunity to make a difference in how these infections are treated in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Serological or molecular evidence of hantavirus infection and clinical evidence of nephropathia epidemica or hemorrhagic fever with renal syndrome (HFRS)
• • Serological or molecular evidence of hantavirus infection and clinical evidence of hantavirus cardiopulmonary syndrome (HCPS)
• Exclusion Criteria:
• • - Serological or molecular evidence of hantavirus infection without clinical signs of nephropathia epidemica, HFRS or HCPS